Podcasts about Pharmacology

On this podcast, I cover ciprofloxacin pharmacology. Ciprofloxacin is one of the most widely recognized fluoroquinolone antibiotics and has been on the market for decades. Because of its broad utility, it often comes up in practice, but it also carries significant adverse effect concerns and boxed warnings that pharmacists and prescribers need to keep in mind. From a pharmacology standpoint, ciprofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication, transcription, and repair. This action gives ciprofloxacin bactericidal activity against a variety of gram-negative organisms, including E. coli, Klebsiella, Enterobacter, and Pseudomonas aeruginosa. It also has some gram-positive activity, though it is generally not the best choice for strep infections. Ciprofloxacin comes in multiple dosage forms, including oral tablets, oral suspension, and intravenous formulations, which makes it flexible across care settings. I discuss the conversion of IV and PO formulations. Pharmacokinetics are important to consider. Ciprofloxacin is primarily renally eliminated, so dose adjustments are necessary in patients with impaired kidney function. Distribution into tissues is generally good, but it has limited activity in the lungs against Streptococcus pneumoniae, which is why it is not a first-line option for community-acquired pneumonia. Adverse effects are a major concern. The fluoroquinolone class carries multiple boxed warnings. Ciprofloxacin has been associated with tendon rupture, peripheral neuropathy, CNS effects such as agitation or seizures, and exacerbation of myasthenia gravis. More recent warnings include the risk for aortic aneurysm and hypoglycemia or hyperglycemia, particularly in older adults or those with comorbidities. On top of these boxed warnings, ciprofloxacin can also prolong the QT interval and cause GI upset. Drug interactions are another big factor in practice. Ciprofloxacin is a CYP1A2 inhibitor, which can raise levels of drugs like theophylline, tizanidine, and clozapine. It also interacts with polyvalent cations such as calcium, magnesium, iron, and aluminum, which can dramatically reduce its absorption—sometimes by more than 50%. This is a common reason for treatment failure if counseling isn't provided. From a dosing perspective, ciprofloxacin is usually given 250–750 mg orally twice daily or 400 mg IV every 8–12 hours depending on the indication and severity of infection. Renal dosing adjustments are needed as kidney function declines. In summary, ciprofloxacin is a powerful antibiotic when used appropriately. It remains an option for urinary tract infections, complicated intra-abdominal infections, and some cases of hospital-acquired pneumonia, but its use must be balanced with the potential for significant adverse effects and interactions. For pharmacists, educating patients on drug interactions, counseling about boxed warnings, and ensuring correct dosing in renal impairment are some of the most valuable interventions when ciprofloxacin shows up on a medication list.

Dr. Chris Masterjohn is the host of the Mastering Nutrition Podcast and founder of Mitome, where he helps people optimize their mitochondrial health through advanced analysis. He received his PhD in Nutritional Sciences from the University of Connecticut, completed his postdoctoral research at the University of Illinois, and served as Assistant Professor at Brooklyn College before choosing to work independently - free from institutional constraints - in science research and education. His groundbreaking SSRI series on his substack hasn't just exposed the truth about these drugs. It's revealed that we've been looking at them completely wrong. Dr. McFillin and Dr. Masterjohn expose how these drugs act as mitochondrial toxins, disrupt cellular energy, and deplete serotonin. They also explore the consequences no one talks about: from prenatal exposure to why so many patients say they feel “dead inside.”Chris Masterjohn, PhD Website Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

On this episode, we define obsessive-compulsive disorder (OCD) and describe its clinical presentations, diagnostic criteria, and underlying pathophysiology. We evaluate current guidelines and evidence-based treatment strategies for managing OCD, including pharmacologic and non-pharmacologic interventions. We also, compare and contrast the efficacy, safety profiles, and appropriate use of selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and other emerging treatment modalities for OCD.  Dr. David Osser's psychopharmacology Algorithm Website  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

On episode 525 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews author and lactation pharmacologist Dr. Kaytlin Krutsch, PhD, PharmD, MBA, BCPS. In the course of their conversation, Keith and Dr. Krutsch discuss the history and science behind the very specialized topic of lactation pharmacology, and why it should be of great importance to all healthcare professionals. Kaytlin Krutsch, PhD, PharmD, MBA, BCPS is a lactation pharmacologist who literally wrote the book on medications in human milk with Dr. Thomas Hale, Hale's Medications and Mothers' Milk. Dr. Krutsch is both Director of the Infant Risk Center and Associate Professor at the Texas Tech University Health Sciences Center, and advises the Food and Drug Administration, the Human Milk Banking Association of Northern America, and the pharmaceutical industry on lactation pharmacology and lactation research. Dr. Krutsch believes families deserve better answers to questions about breastfeeding and medications, and designs research that addresses their questions while creating a comprehensive information cycle that empowers families. This episode of the Nurse Keith Show is brought to you in collaboration with Springer Publishing, who have been delivering award-winning healthcare education and exam prep materials focused on nursing, behavioral health, and the health sciences for more than 70 years. We thank Springer Publishing for their support. Connect with Dr. Kaytlin Krutsch and The Infant Risk Center ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn Instagram Facebook Infant Risk Center website Hale's Medications and Mother's Milk Contact Nurse Keith about holistic career coaching to elevate your nursing and healthcare career at ⁠⁠⁠⁠⁠⁠⁠NurseKeith.com⁠⁠⁠⁠⁠⁠⁠. Keith also offers services as a motivational and keynote speaker and freelance nurse writer. You can always find Keith on⁠⁠⁠⁠⁠⁠⁠ LinkedIn⁠⁠⁠⁠⁠⁠⁠. Are you looking for a novel way to empower your career and move forward in life? Keith's wife, Shada McKenzie, is a gifted astrologer and reader of the tarot who combines ancient and modern techniques to provide valuable insights into your motivations, aspirations, and life trajectory, and she offers listeners of The Nurse Keith Show a 10% discount on their first consultation. Contact Shada at ⁠⁠⁠⁠⁠⁠⁠TheCircelandtheDot.com ⁠⁠⁠⁠⁠⁠⁠or shada@thecircleandthedot.com.

In this episode, Dr. Andy Cutler interviews Dr. Roger McIntyre about the growing recognition of Long COVID and its wide-ranging neuropsychiatric manifestations. They discuss the role of neuroinflammation in its pathophysiology, the impact of these symptoms on patients' daily functioning, and both current and emerging treatment approaches.  Dr. Roger McIntyre is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

On this episode, we define acute mania and describe its clinical presentations, underlying causes, and pathophysiology. We evaluate current guidelines and evidence-based treatment strategies for managing acute mania, including pharmacologic and nonpharmacologic interventions. We also compare and contrast the efficacy, safety profiles, and appropriate use of mood stabilizers, antipsychotics, and adjunctive therapies in the management of acute manic episodes. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Vilazodone (brand name Viibryd) is an antidepressant with a unique pharmacologic profile compared to most other agents in the SSRI class. While not a first-line choice for every patient, understanding its mechanism, adverse effects, and interaction profile is essential for optimizing therapy and preventing downstream prescribing problems. Mechanism of ActionVilazodone is classified as a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the 5-HT1A receptor. The SSRI activity increases synaptic serotonin by blocking the serotonin transporter, while partial agonism at 5-HT1A receptors may contribute to antidepressant effects and potentially reduce certain SSRI-associated adverse effects (though clinical evidence for this benefit is mixed). Adverse Effects GI effects – diarrhea, nausea, and vomiting are frequent early in therapy. Taking the medication with food can help minimize these. Insomnia – often dose-related; morning dosing may help. Sexual dysfunction – may be slightly lower than with some SSRIs but still present. Serotonin syndrome – rare but serious, particularly if combined with other serotonergic drugs. Discontinuation syndrome – abrupt cessation can lead to dizziness, irritability, and flu-like symptoms. Drug InteractionsVilazodone is primarily metabolized by CYP3A4. This means: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase vilazodone concentrations, potentially worsening side effects—dose reductions may be required. CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John's Wort) can lower drug levels, reducing effectiveness. Other serotonergic agents (e.g., triptans, SNRIs, MAOIs, tramadol, linezolid) increase the risk of serotonin syndrome. Antiplatelets and anticoagulants – SSRIs can impair platelet aggregation, increasing bleeding risk when combined with aspirin, NSAIDs, or warfarin. Prescribing Cascade ExamplesVilazodone's adverse effects can easily lead to unnecessary prescriptions if side effects aren't recognized: GI upset → Acid suppression therapy – Diarrhea or nausea prompts the addition of proton pump inhibitors or antiemetics, instead of adjusting vilazodone dose or timing. Insomnia → Hypnotic initiation – Trouble sleeping results in adding zolpidem or trazodone, without reassessing morning dosing or vilazodone's role. Sexual dysfunction → PDE5 inhibitor prescription – Erectile dysfunction leads to sildenafil use, when the root cause is vilazodone's serotonergic activity. Vilazodone's combination of SSRI and 5-HT1A partial agonist activity makes it somewhat distinct, but its side effect profile and interactions require the same careful monitoring as other antidepressants. Healthcare professionals can play a key role in catching early signs of adverse effects, preventing prescribing cascades, and ensuring drug–drug interactions are managed appropriately.

Are typical mouthwash products effective and are they worth recommending to our patients? Are there any products out there that can actually make a significant difference in our fight against perio disease? Our guest, Dr. Steven Milman, will address these questions and more. Dr. Milman received his dental degree from Baylor College of Dentistry in Dallas, Texas. He completed his Periodontal residency at the University of Texas Health Science Center in San Antonio. He was a researcher in periodontal microbiology and was a full time periodontist in his private practice in Round Rock and Austin, Texas for 36 years. Thanks to our episode sponsors: BISCO - https://www.bisco.com/ Solventum - https://www.solventum.com/en-us/home/oral-care/

Do arts interventions and creative engagement really make a difference in our lives and our brains?  Yes, they really do. Come explore what the Neuro Arts movement is all about. In this conversation with Susan Magsamen, the author of Your Brain on Art: How the Arts Transform Us, and Director of The International Arts and Mind Lab at John's Hopkins University School of Medicine, we cover: *Why putting ourselves in the path of AWE is powerful for our brains. *What is Neuro-Plasticity? *How the Saliency Networks in our brains impacts why certain things resonate with us. *Why daydreaming is good for us. *How nature is the ultimate enriched environment for us. *What is the default mode network of our brain? The seat of ourslves or place of rumination? *And what actually causes us to ruminate? *The Aesthetic Triad, how we are wired vs our lived experiences. *The paradigm shift that is happening right now in public health. *Music Break, take a breathe and let go. (*Song: Of Your Own by James Harrell)  *Why Art and Science together is potent medicine. *What is Entrainment and why is it so powerful in arts interventions? *Music Break ( *Song by James Harrell, from documentary film Separate But Equal)  *Arts and Health vs. Pharmacology. *Are the Arts and Sciences dating? Yes and it's getting serious! *Closing song (Alchemy by Ilyana Kadushin and James Harrell)  *Signing off with Ilyana and James and may include some special cat guest! All Music and Lyrics in this episode by James Harrell and Ilyana Kadushin.  Visit: https://www.noiknowpodcast.com  https://www.neuroartsresourcecenter.com/home  

Dr. Charles Shepherd is the Honorary Medical Adviser to the ME Association, a patient charity in London, UK. Dr. Ken Friedman is a retired Associate Professor of Pharmacology and Physiology, New Jersey University of Medicine and Dentistry, Newark, New Jersey. Following up … More ... The post Dr. Charles Shepherd and Dr. Ken Friedman – UK and US Updates on ME/CFS and Long Covid appeared first on Paradigms Podcast.

Solifenacin is a bladder antimuscarinic medication most commonly used for overactive bladder (OAB) with symptoms of urinary frequency, urgency, and urge incontinence. Like other agents in its class, understanding the pharmacology can help anticipate potential side effects, drug interactions, and downstream prescribing problems. Mechanism of Action Solifenacin selectively blocks muscarinic M3 receptors in the bladder detrusor muscle. Inhibiting these receptors reduces involuntary bladder contractions, increases bladder capacity, and delays the urge to void. While M3 selectivity may theoretically reduce side effects compared to nonselective antimuscarinics, in clinical practice, many anticholinergic effects still occur. Adverse Effects Because muscarinic receptors are present throughout the body, solifenacin can lead to a range of anticholinergic adverse effects: Dry mouth – among the most common, can be significant enough to cause dental issues with long-term use. Constipation – especially problematic in older adults; severe cases may require hospitalization. Blurred vision – due to impaired accommodation. Cognitive impairment – increased risk in older adults, particularly with cumulative anticholinergic burden. Urinary retention – paradoxical worsening in patients with bladder outlet obstruction. Drug Interactions CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase solifenacin plasma concentrations, raising the risk of side effects. Other anticholinergics (e.g., diphenhydramine, tricyclic antidepressants, other bladder antimuscarinics) can result in additive toxicity and higher anticholinergic burden. QT-prolonging drugs (e.g., amiodarone, certain fluoroquinolones) may have additive cardiac risk since solifenacin has been associated with QT prolongation in rare cases. Prescribing Cascade Examples Constipation → Laxative initiation – A patient starts solifenacin for OAB and develops severe constipation, leading to chronic use of stimulant laxatives like senna or bisacodyl. Dry mouth → Mouth rinse prescription – Dry mouth is treated with saliva substitutes or prescription rinses, instead of reassessing the anticholinergic therapy. Cognitive decline → Donepezil initiation – In older adults, cognitive impairment may be mistaken for dementia progression, leading to cholinesterase inhibitor prescribing—directly counteracting the anticholinergic effects of solifenacin. Solifenacin can be an effective treatment for OAB, but the risk of adverse effects and prescribing cascades—especially in older adults—cannot be ignored. Healthcare professionals should regularly review the indication, monitor for anticholinergic burden, and look for opportunities to deprescribe when appropriate.

Drug-related deaths are at their highest levels in England and Wales since records began 30 years ago.Scotland has had the highest number of drug deaths in Europe for at least seven years. And the UK has even seen opioid-related deaths surpass the number of people dying in road traffic accidents.So today on Inside Health we're asking, what's the real story behind these numbers? Who is dying of a drug overdose and why - and how can we tackle this issue?James Gallagher is joined by an expert panel, including:- Professor Catriona Matheson, Professor in Substance Use at the University of Stirling and former chair of Scotland's drug deaths taskforce - Dr Caroline Copeland, Senior Lecturer in Pharmacology and Toxicology at King's College London and Director of the National Programme on Substance Use Mortality - Dr Michael Blackmore, a GP in Grangemouth, central Scotland, who has a special interest in addictions and is himself a former drug addict, now 16 years in recoveryWe also visit Professor Sir John Strang at the National Institute for Health and Care Research King's Clinical Research Facility to see how he is experimenting with new ways of tackling rising deaths. Professor Strang is based at the National Addictions Centre, King's College London, and monitors heroin users in the lab to see if this could in future bring about a wearable overdose detection device to save lives.Presenter: James Gallagher Producer Gerry Holt Researcher: Minnie Harrop Editor: Ilan Goodman Production coordinator: Ishmael SorianoIf you've been affected by addiction, details of help and support are available at bbc.co.uk/actionline.This episode was produced in partnership with The Open University.

In this episode of BioTalk, Rich Bendis welcomes Dr. Stacey Adam, Vice President of Science Partnerships, Translational Science at the Foundation for the National Institutes of Health (FNIH), to discuss how public-private partnerships are advancing scientific innovation. Dr. Adam introduces the mission of FNIH and its unique role in bridging government, industry, and academia to accelerate biomedical progress. She highlights the Validation and Qualification Network (VQN), a new initiative working to overcome barriers to the adoption of New Approach Methodologies (NAMs) and explains how cross-sector collaboration is driving its early success. The conversation explores the long-term vision of the VQN, the global perspectives shaping its approach, and how it fits into the broader NIH Complement-ARIE initiative. Dr. Adam also reflects on the significance of being headquartered in the BioHealth Capital Region and how it supports the Foundation's mission.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Guest Bio Dr. Stacey Adam is Vice President of Science Partnerships at the Foundation for the NIH (FNIH), where she leads major public-private partnerships including the RECOVER-Treating Long COVID initiative, multiple Biomarkers Consortium projects, the Accelerating Medicines Partnerships (AMPs), and the Lung-MAP clinical trial. She also leads efforts to design new public-private partnerships focused on pediatric medical devices, cancer systems biology, and the advancement of New Approach Methodologies (NAMs) through the Validation and Qualification Network. Previously, Dr. Adam worked at Deloitte Consulting and completed a postdoctoral fellowship at Stanford University School of Medicine. She holds a PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.

“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44

In this episode, we break down itraconazole—a potent antifungal with a lot of baggage. If you're a pharmacist, clinician, or student who needs to understand how this drug works and why it can be tricky to use, this episode is for you. We start with the basics. Itraconazole blocks 14α-demethylase, an enzyme fungi need to make their cell membranes. That disruption kills or slows the fungus. It works against tough bugs like Aspergillus, Histoplasma, and Blastomyces, plus common skin infections. Side effects? Nausea, liver enzyme elevations, and more seriously, heart failure. Yes, itraconazole has a black box warning for worsening or causing congestive heart failure. If your patient has heart issues, think twice. Drug interactions are everywhere. Itraconazole is a strong CYP3A4 inhibitor. It can raise levels of drugs like statins, benzos, calcium channel blockers, and immunosuppressants—sometimes to dangerous levels. Don't co-prescribe without checking.

Can't pay attention? Well, you're gonna want to save SOME of that attention to learn about ADHD pharmacology, a surprisingly tricky topic made easy by OMS3 Ghazal Adibi!

On this episode, we provide an overview of insulin. We discuss the various insulin products available, basal vs prandial insulin, and dosing strategies. We also review clinical concepts such as overbasalization.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In this episode of the World Extreme Medicine Podcast, host Eoin Walker is joined by expedition doctor, GP, and WEM faculty member Daniel Grace to explore the essential medications needed for remote and high-risk environments.From his recent work in Zambia, Daniel unpacks real-world pharmacology strategies: what drugs matter most, how to balance ideal vs. realistic care, and how to make limited supplies go further in the field.Together, they discuss:The non-negotiables in your expedition med kitAdapting to extreme heat, altitude, and remote terrainPain management without controlled substancesAntibiotics, wound care, and infection controlStorage challenges in hot, cold, and humid conditionsRisk assessment, planning, and reach-back strategies

In this episode of our pharmacology podcast, we take a deep dive into the pharmacology of levomilnacipran (Fetzima), a unique serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD) in adults. Designed for pharmacy students, clinicians, and anyone interested in psychopharmacology, this episode breaks down what makes levomilnacipran different from other antidepressants and how to use it effectively in clinical practice. We explore levomilnacipran's mechanism of action, which features a greater affinity for norepinephrine reuptake inhibition compared to serotonin—an uncommon trait among SNRIs. This pharmacologic profile gives it a distinctive effect on energy, motivation, and physical symptoms of depression. Listeners will also learn about its pharmacokinetics, including once-daily dosing, renal elimination, and metabolism via the CYP3A4 pathway—making drug interactions an important consideration. The episode also covers levomilnacipran side effects, including common adverse reactions like nausea, dry mouth, constipation, and increased heart rate or blood pressure. We'll also highlight rare but serious risks like serotonin syndrome and urinary hesitation. Because levomilnacipran drug interactions can impact safety and efficacy, we review important combinations to avoid, such as CYP3A4 inhibitors (e.g., ketoconazole), serotonergic drugs, and blood pressure-altering agents. For pharmacists and prescribers, this is a key segment to help guide safer medication use and monitoring. Finally, we wrap up with clinical pearls for starting, titrating, and monitoring levomilnacipran therapy—including renal dose adjustments and differences with duloxetine. Whether you're studying for boards or optimizing your patient's antidepressant regimen, this episode delivers a concise, evidence-based overview of levomilnacipran pharmacology in a digestible, podcast-friendly format.

Episode Title: Social Connectedness & Health, with Dr. Cassidy Leibold, PhD!!! Cassidy's Bio: Is a graduate of the University of Dayton (2020) and University of Kentucky, with an MS and PhD in Experimental Psychology. Specifically, she studies Behavioral Neuroscience and Pharmacology. Her research focuses on the excitotoxic effects of alcohol on the hippocampus, and how prolonged alcohol exposure impairs neurogenesis and overall cell survival in this brain structure. She is now a lecturer in the Psychology department at the University of Kentucky, and loves getting to work with aspiring researchers and clinicians. Description: In this episode, Rob welcomes back Dr. Cassidy Leibold, PhD, a lecturer in the Psychology Department at the University of Kentucky. Cassidy shares the exciting developments since her last visit, including her new role teaching aspiring researchers and clinicians. She also reflects on her journey through her PhD, where she studied the effects of chronic binge alcohol use on neurogenesis in the hippocampus—a key brain region involved in memory formation. Cassidy discusses the importance of social connectedness and how our relationships play a significant role in our health. She explores the evolutionary significance of group membership, the brain's response to social pain, and how social media can both connect and amplify relationships. She also explains the delicate balance between the number and quality of social connections, highlighting why quality tends to matter more as we age. Cassidy wraps up the conversation with her personal insights on how she's grown since her PhD, including changes in how she views success, the impact of joining groups that support her, and the importance of personal well-being. Topics Covered: Cassidy's Journey and New Role at the University of Kentucky Cassidy shares her experiences during and after her PhD, discussing the challenges of conducting empirical research and the lessons she's learned along the way. What We Know About Social Connectedness Explore how social connectedness has shaped human survival and how it continues to impact our health today. Cassidy dives into the evolutionary psychology behind group membership and why being part of a group is so deeply ingrained in our brains. Quality vs. Quantity in Social Relationships Cassidy talks about the importance of both the number and quality of connections, explaining why the quality of relationships becomes more important with age and how our closest relationships influence our behaviors and beliefs. The Elevate Yourself Podcast is brought to you in partnership with Athletic Brewing. Use code ELEVATE30 for 30% OFF your first online order at checkout!

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Asenapine is an atypical antipsychotic that acts as an antagonist at multiple receptors, including dopamine D2 and serotonin 5-HT2A, contributing to its antipsychotic and mood-stabilizing effects. Adverse effects of asenapine include somnolence, dizziness, and extrapyramidal symptoms. Because asenapine is significantly metabolized by CYP1A2, inhibitors or inducers of these enzymes can affect its plasma concentrations. Co-administration with other CNS depressants may increase the risk of sedation and impaired cognitive or motor function. Asenapine can prolong the QT interval, so caution is advised when used with other medications that affect cardiac conduction.

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35

Pharmacology can be a bit confusing when you are first learning about how drugs enter and are processed by the body. It is a very important concept to know well as we move forward with the administration of local anesthesia.In this episode, we will review Potency, efficacy, and the therapeutic index. I will go over ways to remember each in a way that creates learning and understanding. You can do this! Other Resources:Tutoring with Me: ⁠⁠⁠https://calendly.com/d/cszb-s4r-hy4/tutoring-with-billie⁠⁠⁠Leave me a message or send a question I can share on the Podcast⁠⁠⁠⁠ Here⁠⁠⁠⁠Time Management Prioritization Quiz - Find out how you rate ⁠⁠⁠⁠⁠HERE ⁠⁠⁠⁠Study Sheets: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thehappyflosserrdh.etsy.com/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Specialized Course: How to be successful in Dental Hygiene School⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://billie-lunt-s-school.teachable.com/p/how-to-be-successful-in-dental-hygiene-school⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Other Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠blog.feedspot.com/dental_hygiene_podcasts/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Email Me: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠HappyflosserRDH@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Leave me a message or ask a question I can share on the Podcast ⁠Here ⁠Time Management Prioritization Quiz - Find out how you rate ⁠⁠HERE ⁠Check out my free scorecard for students - you can rank yourself on how you are doing to take action on the steps toward being a successful college student. Sign up on the Google doc ⁠⁠⁠⁠HERE⁠⁠⁠⁠ - I will send along your scorecard to use the entire time you are enrolled in school. Study Sheets: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thehappyflosserrdh.etsy.com/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Specialized Course: How to be successful in Dental Hygiene School⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://billie-lunt-s-school.teachable.com/p/how-to-be-successful-in-dental-hygiene-school⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Other Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠blog.feedspot.com/dental_hygiene_podcasts/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Tooth fairy escape room ⁠⁠⁠Here ⁠⁠⁠Email Me: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠HappyflosserRDH@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Billie Lunt Media Kit: ⁠https://www.canva.com/design/DAGaiUvmKTI/R8NEtEIUAwS9pptthWb6QQ/view?utm_content=DAGaiUvmKTI&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=hb5fb9186b2⁠

Update on Missing kids in Nova Scotia Guest: Lindsay Jones, reporter for the Globe and Mail Iranian immigration into Canada Guest: Ram Joubin, Immigration Lawyer,  Iranian-Canadian who specializes in refugee and human-rights law Do we need to regulate the amount of THC in cannabis products? Guest: Ruth A. Ross, Ph.D.  Professor, Department of Pharmacology & Toxicology, University of Toronto Weekly Cecchini Check-In Guest: Reggie Cecchini, Washington Correspondent for Global News Police charge a man who's been impersonating a police officer Guest: Corporal Mansoor Sahak, North Van RCMP Learn more about your ad choices. Visit megaphone.fm/adchoices

Do we need to regulate the amount of THC in cannabis products? Guest: Ruth A. Ross, Ph.D.  Professor, Department of Pharmacology & Toxicology, University of Toronto Learn more about your ad choices. Visit megaphone.fm/adchoices

Loxapine is a first-generation (typical) antipsychotic with dopamine D2 receptor antagonism as its primary mechanism, though it also has affinity for serotonin 5-HT2A receptors, making its pharmacology somewhat atypical. Loxapine is available in multiple formulations, including oral capsules and an inhalation powder, the latter approved specifically for acute agitation in patients with schizophrenia or bipolar I disorder. Sedation and extrapyramidal symptoms (EPS), including dystonia, akathisia, and parkinsonism, are common adverse effects due to its potent dopamine blockade in the nigrostriatal pathway. Orthostatic hypotension can occur with loxapine due to its alpha-1 adrenergic blockade, requiring monitoring in elderly patients or those on antihypertensives.

Are you preparing to start dental hygiene school soon? If so, this is the perfect episode for you! Marie Richey, a current dental hygiene educator, joins me on this episode to give insider tips and tricks for incoming and current students. Listen to her perspective as a professor to have a clear understanding of what dental hygiene school will look like and be ready to go on your first day!Timestamps: (00:00) Marie's RDH Origin Story (04:03) Working as a Travel Dental Hygienist (11:51) Marie's Tips and Tricks for Dental Hygiene Students (21:16) Struggling in Pharmacology (30:08) Don't Stop Learning Dental Hygiene

What if everything you thought about trauma and healing was missing one simple truth—that you are not broken?In this deeply inspiring episode, we sit down with Academy Award-winning Hollywood veteran turned trauma recovery expert, Chana Studley, to explore a radically different approach to healing. After surviving three brutal muggings, battling severe PTSD, and struggling with chronic pain for years, Chana discovered something life-changing: true healing doesn't come from doing more—it comes from understanding more.Chana shares her remarkable journey of transformation, from years of physical and emotional suffering to a thriving life of purpose, peace, and creativity.She introduces us to a powerful new paradigm rooted in the understanding that we are not our thoughts, and that well-being isn't something to chase—it's something we already have within us.We talk about:The moment that sparked Chana's healingWhy trying to “fix” ourselves can keep us stuckThe truth about anxiety, chronic pain, and the stories we carryWhat it really means to “settle” the mindHow insight, not effort, opens the door to lasting peaceWhether you're navigating trauma, anxiety, chronic pain, or simply feeling overwhelmed by the constant pressure to improve, this conversation is your invitation to breathe, let go, and remember who you truly are.Because healing isn't hard when you realise—you were never broken to begin with.Chana Studley is a coach, counselor, international speaker, and author with over 35 years of experience in the field of mental health.After surviving three violent muggings in the 1980s and living with severe PTSD, Chana went on to build an award-winning career in Hollywood, including receiving an Academy Award for her work in special effects.Her personal journey from trauma to healing eventually led her to train as a counselor with the Manchester Women in Crisis Center and later become a certified Life Coach and Three Principles Practitioner.In 2018, Chana graduated from The One Thought Institute and has since become a leading voice in the field of mind-body health, particularly through her pioneering work with the Three Principles and the connection between psychological and physical well-being.She is also a World Health Organization Psychological First Responder and holds diplomas in both Psychology and Pharmacology.Chana is the founder of the Beyond Chronic Pain Masterclass, an accessible six-hour online course designed to empower individuals suffering from chronic pain through a new understanding of healing.Chana is the author of four books, including Beyond Diagnosis: A Paradigm Shift from Pathology to Innate Health, and three Amazon #1 bestselling novels—The Myth of Low Self-Esteem, Painless, and Very Well—which blend storytelling with insights on trauma, chronic pain, and hormonal health.Her work has been praised for offering fresh hope and clarity to those overwhelmed by pain and psychological distress. She is also a proud member of United Hatzalah and continues to support individuals and communities around the world through her coaching and writing.Find out more and connect with Chana online:Book website: beyond-diagnosis.comWebsite: chanastudley.comLinkedIn: https://www.linkedin.com/in/chanastudley/Facebook: https://www.facebook.com/groups/understandinganxietystressandtrauma

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing insomnia, including both pharmacological and non-pharmacological approaches. We compare and contrast the efficacy, safety profiles, and appropriate use of pharmacologic agents, behavioral therapies, and lifestyle interventions for treating insomnia.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaWatch it: https://www.youtube.com/watch?v=6Ihq4tIzyS8&t=5618sRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 Intro  00:02:40 Personal Life Updates  00:04:51 Pregnancy and Lifestyle Changes  00:10:57 Early Steroid Use and Coaching  00:18:43 Sleep Schedules and Productivity  00:26:45 Bodybuilding Industry Evolution  00:27:52 Modern Bodybuilding Aesthetics  00:37:31 GLP-1 Agonists and Nutrition  00:41:37 Classic Physique and Weight Caps  00:46:51 Coaching and Knowledge Evolution  00:53:07 Family Genetics and Hard Work  00:56:55 Diminishing Returns With Protein  01:08:23 Growth Hormone Dosing Insights  01:16:41 Insulin and GH Combinations  01:22:54 Elite Coaching and Drug Testing  01:27:17 Insulin Resistance Myths  01:32:30 Social Media Arguments01:34:38 Trenbolone and Kidney Concerns  01:39:30 Smart Drug Choices in Bodybuilding  01:49:55 Living In Thailand01:56:35 HGH Timing 02:06:30 Tirzepatide vs. Retatrutide  02:12:00 Prescriptions and Traveling02:16:58 Reversing LVH Growth  02:22:42 Estradiol Levels on Cycle  02:27:04 Anabolic Synonymous Shutdown02:30:45 Classic Physique Drug Use 02:33:40 Life Updates and Fatherhood

The Daily Quiz - Science and Nature Today's Questions: Question 1: In Computing, What Does The Abbreviation USB Stand for Question 2: Which organ stores urine? Question 3: What is Dermatopathology the study of? Question 4: What is Pharmacology the study of? Question 5: Who Invented The Telephone? Question 6: What are the two different values of the square root of 144? Question 7: What is Astacology the study of? Question 8: What would you call a female bird? Question 9: What is a female pig known as? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Ketoconazole is an imidazole antifungal that works by inhibiting fungal cytochrome P450 14α-demethylase, an enzyme essential for ergosterol synthesis, which disrupts fungal cell membrane integrity. Common adverse effects of ketoconazole include nausea, vomiting, abdominal pain, and elevated liver enzymes, with hepatotoxicity being a notable concern. Ketoconazole carries a boxed warning for severe hepatotoxicity, including cases of liver failure and death, and should not be used as a first-line treatment for fungal infections when other safer antifungals are available. Another boxed warning highlights ketoconazole's potential to prolong the QT interval, increasing the risk for life-threatening ventricular arrhythmias such as torsades de pointes. Ketoconazole is a strong inhibitor of CYP3A4 and can cause significant drug interactions by increasing serum concentrations of medications metabolized by this pathway, including statins, certain benzodiazepines, and some antiarrhythmic.

The Science Behind Chemical Sensitivity with Haylie Pomroy and Dr. Theoharis Theoharides Support the Institute today. https://www.nova.edu/give/index.html?area=Institute%20for%20Neuro-Immune%20Medicine&designation=INIM%20Grateful%20Patient%20Fund  In this episode, Dr. Theoharis Theoharides breaks down the science behind Multiple Chemical Sensitivity (MCS), offering a clear and research-informed perspective on this often misunderstood condition.  He defines what MCS is, how individuals can be triggered by even minimal chemical exposures, and the wide range of symptoms that may follow. He also addresses the serious immunological effects of chemical exposure and emphasizes the importance of creating chemically safe environments. The discussion also covers the role of mast cell activation in MCS, the ways stress can intensify symptoms, and the diagnostic codes currently used for clinical management and treatment.  Tune in to the Hope and Help for Fatigue and Chronic Illness Podcast – The Science Behind Chemical Sensitivity Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html  Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx   Dr. Theoharis Theoharides is a Professor, Vice Chair of Clinical Immunology, and Director at the Institute for Neuro-Immune Medicine-Clearwater, an Adjunct Professor of Immunology at Tufts School of Medicine, where he was a Professor of Pharmacology and Internal Medicine, and also the  Director of Molecular Immunopharmacology & Drug Discovery, and Clinical Pharmacologist at the Massachusetts Drug Formulary Commission (1983-2022). He received his BA, MS, MPhil, PhD, and MD degrees and the Winternitz Price in Pathology from Yale University and received a Certificate in Global Leadership from Tufts Fletcher School of Law and Diplomacy and a Fellowship at Harvard Kennedy  School of Government. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award, “recognizing excellence, compassion, and service.” Dr. Theoharides has 485 publications (46,491 citations; h-index 106), placing him in the world's top 2% of most cited authors, and he was rated the worldwide expert on mast cells by Expertscape. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences.  Website: https://www.drtheoharides.com  LinkedIn: linkedin.com/in/theoharis-theoharides-ms-phd-md-faaaai-67123735   Instagram: https://www.instagram.com/dr.theoharides/   Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet. Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy  Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others. You can also find this show on our YouTube channel. Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d Learn more about the Institute for Neuro-Immune Medicine. Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Episode 07 - Ben Malcom: The Spirit Pharmacist This all new episode of the Psychedelics Then and Now Podcast features an all new interview with the ever wise and important Ben Malcom, The Spirit Pharmacist. Ben's knowledge of psychedelic compounds, drug interactions, safe use and pharmacological histories holds a unique place in today's psychedelic culture. His welcoming approach to very complicated topics really sets him apart from other scientific luminaries. Our conversation illuminated so many nooks and crannies within this ever expanding knowledge base. Also, the intro brings classic 1977 Ram Dass's take on cognitive liberty and consciousness exploration. (Thank you to the Love Serve Remember Foundation) About Ben Malcom I envision a society in which access to psychedelic drugs in a variety of safe settings is available for purposes of psychospiritual well-being, personal development, ceremonial sacraments, and treatment of mental illness. I strive to let my loves and passions guide my activity and provide the canvas my life is painted on. I hope this site can be of service to my vision as well as you. Professionally, I was trained as a clinical psychiatric pharmacist and worked in academia for almost five years before dedicating myself to Spirit Pharmacist. Today I provide psychopharmacology consulting, courses in psychedelic pharmacy, and a Member Resource and Support Program. On a more personal note, I'm a lover of nature, exercise, music, and consciousness as well as being a father. I'm passionate about cognitive liberty, self-realization, and psychedelic drugs.

Bailey presents with a history of osteoarthritis and hypertension and is referred to physical therapy for knee pain management. She reports taking over-the-counter medication daily for pain relief. During the session, she mentions experiencing mild stomach discomfort and occasional dizziness. Her blood pressure is 138/86 mmHg. Which medication is MOST likely contributing to the patient's symptoms?A) AcetaminophenB) IbuprofenC) Calcium-channel blockerD) Glucosamine supplementDOWNLOAD THIS EPISODE'S CHEATSHEET:www.nptecheatsheet.com/common-med

Michael Barry, Adjunct Associate Professor, Pharmacology & Therapeutics and Clinical Director National Centre for Pharmacoeconomics, outlines how much pharmaceutical companies are paying out to healthcare professionals and organisations.

SAT's getting shorter to match diminished attention spans of college applicants; Comprehensive review finds most of the studies on which we base our most accepted drugs and medical therapies are flawed; A heart drug approved in 2011 and used by millions comes under renewed scrutiny due to research irregularities; Best supplements for preventing osteoporosis; Tremors after Covid shot; Researchers discover how exercise lowers Alzheimer's risk; Two new studies show exercise curbs cancer recurrence.

Send us a textWrapping up Season 11, Cara and Missi dig deep into their fan mail bag to answer questions from listeners spanning clinical practice, education, and professional development. With their characteristic warmth and wisdom, they tackle everything from postpartum mental health screening to specialized pharmacology knowledge that you won't find in textbooks.The conversation flows through practical clinical topics, starting with the importance of comprehensive mental health screening for postpartum patients.  They share touching feedback from colleagues about creating supportive collaborative practices with physicians, highlighting how direct, respectful communication builds successful interprofessional relationships.For students and new midwives, the hosts offer a treasure trove of specialized resources. They offer insights to suturing resources, discuss scope of practice questions, and answer questions galore. Pharmacology pearls abound as they discuss innovative approaches to breakthrough bleeding, the exact formulation for All-Purpose Nipple Ointment for treating breast yeast infections, and compounded antiemetic gels for pregnancy nausea.Before previewing exciting topics for Season 12—including ovarian masses, cancer screening, osteoporosis, fertility treatments, and AI in midwifery—Cara and Missi remind listeners of the best ways to reach them with questions. Their generosity in sharing expertise and resources demonstrates why this podcast has become such a valuable companion for midwives at every career stage.Email your questions directly to missi@deliveredexamprep.com or cara@deliveredexamprep.com to become part of future episodes, and visit deliveredexamprep.com to access the resources mentioned throughout this knowledge-packed finale.

Lotrisone is a topical cream that contains a combination of clotrimazole, an antifungal, and betamethasone dipropionate, a corticosteroid. It is used to treat fungal skin infections such as athlete's foot, jock itch, and ringworm that also involve inflammation or itching. Clotrimazole works by disrupting the fungal cell membrane, while betamethasone reduces redness, swelling, and itching. Lotrisone should not be used on the face, groin, or underarms for extended periods due to the risk of skin thinning and other steroid-related side effects.

On this episode, we evaluate current guidelines and evidence-based strategies for managing chronic pain, including both pharmacologic and non-pharmacologic options. We compare and contrast the efficacy, safety profiles, and appropriate use of various analgesic classes and adjuvant therapies in chronic pain management. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Fluphenazine is a high-potency typical antipsychotic that primarily acts as a dopamine D2 receptor antagonist in the mesolimbic pathway, reducing positive symptoms of schizophrenia. Extrapyramidal symptoms (EPS), such as dystonia, akathisia, and parkinsonism, are common due to potent D2 blockade in the nigrostriatal pathway. Neuroleptic malignant syndrome (NMS), though rare, is a life-threatening adverse effect characterized by rigidity, hyperthermia, altered mental status, and autonomic instability. CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase fluphenazine plasma concentrations, potentially raising the risk of toxicity and side effects. Concomitant use of fluphenazine with CNS depressants (e.g., alcohol, benzodiazepines) can enhance sedation and respiratory depression.

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode 116, which is all about pediatric pharmacology. When you understand these key foundation concepts, the whole subject of pharm gets a whole lot easier. Enjoy! As cute and adorable as they are, kids are not just tiny adults. Especially when it comes to pharmacology. The way kids absorb, distribute, metabolize and excrete drugs varies greatly, making pediatric pharmacology a truly unique subject.  If you're heading into your pediatric rotation or starting out as a new pediatric RN, then pop in those earbuds. I'll talk you through the key things you need to know to utilize medications safely in this very special and vulnerable population.  ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Dosage Calculations Guide⁠ - Kick math anxiety to the curb and learn the basics of how to set up and perform dosage calculations using dimensional analysis with this FREE guide. Includes 10 free practice questions! ⁠Pharmacology Success Pack⁠ - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack.  ⁠Fast Pharmacology⁠ - Learn pharmacology concepts in 5 minutes or less in this audio based program. Perfect for on-the-go review! ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store.

On this podcast episode, I discuss quinapril pharmacology, adverse effects, drug interactions, pharmacokinetics, and much more. Quinapril is a prodrug that is converted in the liver to its active metabolite, quinaprilat, which inhibits ACE, leading to decreased formation of angiotensin II and reduced aldosterone secretion. Hyperkalemia can occur with quinapril use due to decreased aldosterone, leading to potassium retention—especially in patients with renal impairment. Concomitant use of potassium-sparing diuretics or potassium supplements with quinapril increases the risk of hyperkalemia. NSAIDs may reduce the antihypertensive effect of quinapril and increase the risk of nephrotoxicity, especially in patients with preexisting renal dysfunction.

GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery. But what happens after the weight is lost? And can we really talk about success without talking about maintenance? While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next. Can lifestyle interventions alone sustain weight loss after GLP-1 cessation? How do metabolic adaptations and behavioral relapse factor in? And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications? In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management. Tara Schmidt is a registered dietitian and an instructor of nutrition at Mayo Clinic. As the lead dietitian for the Mayo Clinic Diet, she provides guidance rooted in evidence-based principles. She hosts the Mayo Clinic On Nutrition podcast and co-authored The Mayo Clinic Diet: Weight Loss Medications Edition. Timestamps [05:17] Understanding weight loss maintenance [08:44] Defining success in weight loss maintenance [11:54] Predictors of maintenance: self-monitoring and behavioral strategies [23:37] Pharmacological interventions: GLP-1 receptor agonists [31:06] Dietary considerations for those taking GLP-1 RAs [37:07] Addressing misconceptions about weight loss drugs [42:48] Final thoughts and takeaways [48:49] Key ideas (Premium-only) Links/Resources Subscribe to Sigma Nutrition Premium Go to episode page Join the Sigma email newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course Visit sigmanutrition.com

Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance. The extended-release formulation of nifedipine provides more stable plasma concentrations and is preferred for chronic management of hypertension and angina. Common adverse effects include headache, flushing, peripheral edema, and dizziness, all related to its vasodilatory action. Nifedipine undergoes extensive first-pass metabolism in the liver, primarily via CYP3A4 enzymes, which significantly influences its bioavailability and potential drug interactions. CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) can increase plasma levels of nifedipine, raising the risk of hypotension and adverse effects.

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing GAD. We define generalized anxiety disorder (GAD) and describe its clinical presentations, diagnostic criteria, and underlying pathophysiology. We also compare and contrast the efficacy, safety profiles, and appropriate use of anxiolytic medications, cognitive behavioral therapy, and lifestyle modifications in treating GAD. Dr. David Osser's Website: https://psychopharm.mobi/algo_live/ Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com